InsidersTradesSigma
Total declarations
Companies
▲ Purchases (24 ops.)
▼ Sales (5 ops.)
Insider track record
CFODisclosed buys
24
Disclosed sells
5
T+90 hit rate
43%
T+90 mean return
+14.5%
Across 7 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Discover the detailed record of transactions filed by O'Toole David D, Chief Financial Officer. Director active across 2 companies, notably Opiant Pharmaceuticals, INC.. Aggregated, 38 filings have been published. Split: 24 buys · 5 sells. Total volume traded: €333k. Activity tracked since 16 August 2021. The latest transaction was disclosed on 12 June 2026 (Acquisition). Regulator: SEC (Form 4). The full history is free.
Companies and markets linked to O'Toole David D
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations38 total
2,000 shares@ US$3.970.0036% mcap2.4% of flowCommon StockSEC:0001193125-26-363747:0
Canonical exit: 10 Sept 2026 (T+90)
2,000 sharesCommon StockSEC:0001193125-26-269544:0
5,000 shares@ US$3.05150.0070% mcap5.1% of flowCommon StockSEC:0001193125-26-251588:0
2,000 shares@ US$4.240.0039% mcap2.9% of flowCommon StockSEC:0001193125-26-230874:0
Canonical exit: 17 Aug 2026 (T+90)
1,800 shares@ US$4.782.6% of flowCommon StockSEC:0001193125-26-102263:0
Canonical exit: 9 Jun 2026 (T+90)
3,000 shares@ US$4.153.7% of flowCommon StockSEC:0001193125-26-064111:0
Canonical exit: 20 May 2026 (T+90)
105,470 sharesCommon StockSEC:0001193125-26-059552:0
2,000 shares@ US$4.523.0% of flowCommon StockSEC:0000950170-25-111467:0
Canonical exit: 24 Nov 2025 (T+90)
2,000 shares@ US$4.813.2% of flowCommon StockSEC:0000950170-25-107387:0
Canonical exit: 10 Nov 2025 (T+90)
1,923 shares@ US$4.7773.1% of flowCommon StockSEC:0000950170-25-080304:0
1,000 shares@ US$9.903.7% of flowCommon StockSEC:0000950170-25-024204:0
Canonical exit: 21 May 2025 (T+90)
1,000 shares@ US$10.253.8% of flowCommon StockSEC:0000950170-25-023233:0
Canonical exit: 20 May 2025 (T+90)
785 shares@ US$7.832.3% of flowCommon StockSEC:0000950170-24-133748:0
500 shares@ US$9.201.7% of flowCommon StockSEC:0000950170-24-068006:0
Canonical exit: 28 Aug 2024 (T+90)
1,000 shares@ US$17.386.3% of flowCommon StockSEC:0000950170-24-022050:0
Canonical exit: 28 May 2024 (T+90)
950 shares@ US$12.454.3% of flowCommon StockSEC:0000950170-23-069750:0
Canonical exit: 11 Mar 2024 (T+90)
1,034 shares@ US$9.0613.3% of flowCommon StockSEC:0000950170-23-067875:0
1,000 shares@ US$10.303.7% of flowCommon StockSEC:0000950170-23-065502:0
Canonical exit: 19 Feb 2024 (T+90)
1,000 shares@ US$10.263.7% of flowCommon StockSEC:0000950170-23-065502:1
Canonical exit: 19 Feb 2024 (T+90)
1,000 shares@ US$12.154.4% of flowCommon StockSEC:0000950170-23-064444:0
Canonical exit: 14 Feb 2024 (T+90)
1,000 shares@ US$12.884.7% of flowCommon StockSEC:0000950170-23-064208:0
Canonical exit: 12 Feb 2024 (T+90)
1,000 shares@ US$17.056.1% of flowCommon StockSEC:0000950170-23-043056:0
Canonical exit: 14 Nov 2023 (T+90)
1,000 shares@ US$17.926.4% of flowCommon StockSEC:0000950170-23-042840:0
Canonical exit: 13 Nov 2023 (T+90)
1,000 shares@ US$17.946.4% of flowCommon StockSEC:0000950170-23-042840:3
Canonical exit: 13 Nov 2023 (T+90)
1,000 shares@ US$17.936.4% of flowCommon StockSEC:0000950170-23-042840:4
Canonical exit: 13 Nov 2023 (T+90)
25 of 38 declarations
About O'Toole David D
O'Toole David D is Directeur Financier at AVITA Medical, Inc. and Chief Financial Officer at Opiant Pharmaceuticals, INC. He has 37 filings, and across the recent sampled filings the buys amount to EUR 257269 and the sells to EUR 490677, from 2021-08-16 to 2026-06-12. The modal transaction nature is Acquisition.
